Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPID Extension: Zemaira in Emphysema due to Alpha-1 Antitrypsin Deficiency
NCT00670007Phase 4Completed
- Sponsor
- CSL Limited
- Start
- Apr 2008
- Primary completion
- Sep 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
Phase 4, open-label, single-arm trial of alpha1-proteinase inhibitor in alpha-1 antitrypsin deficiency (AATD), sponsored by CSL Limited. Primary endpoint: Rate of Change of Adjusted Lung Density at 2 years. Started Apr 2008; status: completed.
02
Drugs
alpha1-proteinase inhibitor
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT00670007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00670007.